Literature DB >> 12367562

Cardiac 5-HT(4) serotoninergic receptors, 52kD SSA/Ro and autoimmune-associated congenital heart block.

Jill P Buyon1, Robert Clancy, Francis Di Donato, M Eugenia Miranda-Carus, Anca D Askanase, Joanne Garcia, Yongxia Qu, Keli Hu, Yuankun Yue, Edward K L Chan, Mohamed Boutjdir.   

Abstract

It was recently reported that sera from patients with systemic lupus erythematosus contain antibodies reactive with the second extracellular loop of the serotoninergic 5-HT(4) receptor expressed in the human heart. This antibody response was associated with antibodies to 52kD SSA/Ro, a reactivity prevalent in mothers of children with congenital heart block (CHB). The current study was undertaken to determine whether the 5-HT(4) receptor is a target of the immune response in these mothers. Initial experiments demonstrated mRNA expression of the 5-HT(4) receptor in the human foetal atrium. Electrophysiologic studies established that human foetal atrial cells express functional 5-HT(4) receptors. Sera from 116 mothers enrolled in the Research Registry for Neonatal Lupus, whose children have CHB, were evaluated. Ninety-nine (85%) of these maternal sera contained antibodies to SSA/Ro, 84% of which were reactive with the 52kD SSA/Ro component by immunoblot. None of the 116 sera were reactive with the peptide spanning aa165-185 of the serotoninergic receptor. Rabbit antisera which recognized this peptide did not react with 52kD SSA/Ro or peptide aa365-382 in the C terminus. Although 5-HT(4) receptors are present and functional in the human foetal heart, maternal antibodies to the 5-HT(4) receptor are not associated with the development of CHB.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12367562     DOI: 10.1006/jaut.2002.0594

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

Review 1.  Indications for fetal echocardiography.

Authors:  M Small; J A Copel
Journal:  Pediatr Cardiol       Date:  2004 May-Jun       Impact factor: 1.655

Review 2.  Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk.

Authors:  J P Buyon; R M Clancy; D M Friedman
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

3.  Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block.

Authors:  Robert M Clancy; Petra J Neufing; Ping Zheng; Marguerita O'Mahony; Falk Nimmerjahn; Tom P Gordon; Jill P Buyon
Journal:  J Clin Invest       Date:  2006-08-10       Impact factor: 14.808

Review 4.  Role of calcium channels in congenital heart block.

Authors:  E Karnabi; M Boutjdir
Journal:  Scand J Immunol       Date:  2010-09       Impact factor: 3.487

Review 5.  Maternal antibodies and developing blood-brain barrier.

Authors:  Czeslawa Kowal; Andrew Athanassiou; Huiyi Chen; Betty Diamond
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

Review 6.  Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus.

Authors:  Deborah M Friedman; Ann Rupel; Jill P Buyon
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

Review 7.  Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside.

Authors:  Jill P Buyon; Robert M Clancy; Deborah M Friedman
Journal:  Nat Clin Pract Rheumatol       Date:  2009-03

Review 8.  Neonatal lupus: clinical features and management.

Authors:  Lela A Lee
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block.

Authors:  Christine Fritsch; Johan Hoebeke; Hayet Dali; Vincent Ricchiuti; David A Isenberg; Olivier Meyer; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.